Clinical Trial Update: 1.2% Rosuvastatin Subgingivally Delivered In Chronic Periodontitis With Type 2 Diabetes Mellitus [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluated 1.2% rosuvastatin delivered subgingivally for chronic periodontitis in individuals with type 2 diabetes; the study status is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Periodontitis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: Government Dental College and Research Institute, Bangalore | Conditions: Chronic Periodontitis, Type2 Diabetes | Phase 2, Phase 3 | Status: COMPLETED